P
Pellegrino Musto
Researcher at University of Bari
Publications - 678
Citations - 24375
Pellegrino Musto is an academic researcher from University of Bari. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 70, co-authored 596 publications receiving 20696 citations. Previous affiliations of Pellegrino Musto include Catholic University of the Sacred Heart & University of Bologna.
Papers
More filters
Journal ArticleDOI
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
Antonio Palumbo,Hervé Avet-Loiseau,Stefania Oliva,Henk M. Lokhorst,Hartmut Goldschmidt,Laura Rosiñol,Paul G. Richardson,S. Caltagirone,Juan J. Lahuerta,Thierry Facon,Sara Bringhen,Michel Attal,Roberto Passera,Andrew Spencer,Massimo Offidani,Shantanu Kumar,Pellegrino Musto,Sagar Lonial,Maria Teresa Petrucci,Robert Z. Orlowski,Elena Zamagni,Gareth J. Morgan,Maletios A. Dimopoulos,Brian G.M. Durie,Kenneth C. Anderson,Pieter Sonneveld,Jesús F. San Miguel,Michele Cavo,S. Vincent Rajkumar,Philippe Moreau +29 more
TL;DR: The R-ISS is a simple and powerful prognostic staging system, and it is recommended for use in future clinical studies to stratify patients with NDMM effectively with respect to the relative risk to their survival.
Journal ArticleDOI
BRAF mutations in hairy-cell leukemia
Enrico Tiacci,Vladimir Trifonov,Gianluca Schiavoni,Antony B. Holmes,Wolfgang Kern,Maria Paola Martelli,Alessandra Pucciarini,Barbara Bigerna,Roberta Pacini,Victoria A. Wells,Paolo Sportoletti,Valentina Pettirossi,Roberta Mannucci,Oliver Elliott,Arcangelo Liso,Achille Ambrosetti,Alessandro Pulsoni,Francesco Forconi,Livio Trentin,Gianpietro Semenzato,Giorgio Inghirami,Monia Capponi,Francesco Di Raimondo,Caterina Patti,Luca Arcaini,Pellegrino Musto,Stefano Pileri,Claudia Haferlach,Susanne Schnittger,Giovanni Pizzolo,Robin Foà,Laurent Farinelli,Torsten Haferlach,Laura Pasqualucci,Raul Rabadan,Brunangelo Falini +35 more
TL;DR: The BRAF V600E mutation was present in all patients with HCL who were evaluated, and may have implications for the pathogenesis, diagnosis, and targeted therapy of HCL.
Journal ArticleDOI
Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial
Antonio Palumbo,Sara Bringhen,Tommaso Caravita,Emanuela Merla,Vincenzo Capparella,Vincenzo Callea,Clotilde Cangialosi,Mariella Grasso,Fausto Rossini,Monica Galli,Lucio Catalano,Elena Zamagni,Maria Teresa Petrucci,Valerio De Stefano,Manuela Ceccarelli,Maria Teresa Ambrosini,Ilaria Avonto,Patrizia Falco,Giovannino Ciccone,Anna Marina Liberati,Pellegrino Musto,Mario Boccadoro +21 more
TL;DR: Oral MPT is an effective first-line treatment for elderly patients with multiple myeloma and anticoagulant prophylaxis reduces frequency of thrombosis.
Journal ArticleDOI
Autologous transplantation and maintenance therapy in multiple myeloma
Antonio Palumbo,Federica Cavallo,Francesco Di Raimondo,Dina Ben Yehuda,Maria Teresa Petrucci,Sara Pezzatti,Tommaso Caravita,Chiara Cerrato,Elena Ribakovsky,Mariella Genuardi,Anna Maria Cafro,Magda Marcatti,Lucio Catalano,Massimo Offidani,Angelo Michele Carella,Elena Zamagni,Francesca Patriarca,Pellegrino Musto,Andrea Evangelista,Giovannino Ciccone,Paola Omedè,Claudia Crippa,Paolo Corradini,Arnon Nagler,Mario Boccadoro,Michele Cavo +25 more
TL;DR: Consolidation therapy with high-dose melphalan plus stem-cell transplantation, as compared with MPR, significantly prolonged progression-free and overall survival among patients with multiple myeloma who were 65 years of age or younger.
Journal ArticleDOI
Cardiovascular Events and Intensity of Treatment in Polycythemia Vera
Roberto Marchioli,Guido Finazzi,Giorgina Specchia,Rossella R. Cacciola,Riccardo Cavazzina,Daniela Cilloni,Valerio De Stefano,Elena Maria Elli,Alessandra Iurlo,Roberto Latagliata,Francesca Lunghi,Monia Lunghi,Rosa Maria Marfisi,Pellegrino Musto,Arianna Masciulli,Caterina Musolino,Nicola Cascavilla,Giovanni Quarta,Maria Luigia Randi,Davide Rapezzi,Marco Ruggeri,Elisa Rumi,Anna Rita Scortechini,Simone Santini,Marco Scarano,Sergio Siragusa,Antonio Spadea,Alessia Tieghi,Emanuele Angelucci,Giuseppe Visani,Alessandro M. Vannucchi,Tiziano Barbui +31 more
TL;DR: In patients with polycythemia vera, those with a hematocrit target of less than 45% had a significantly lower rate of cardiovascular death and major thrombosis than did those with an intended target of 45 to 50%.